Soluble vascular endothelial growth factor receptors 2 (sVEGFR-2) and 3 (sVEGFR-3) and breast cancer risk in the Swedish Mammography Cohort
2016 (English)In: International Journal of Molecular Epidemiology and Genetics, ISSN 1948-1756, E-ISSN 1948-1756, Vol. 7, no 1, 81-86 p.Article in journal (Refereed) Published
Vascular endothelial growth factor (VEGF) is a signalling protein that has been established as a contributor to tumor angiogenesis, and expression of VEGF and its soluble receptors (sVEGFR2 and sVEGFR3) have been demonstrated in breast cancer cells. However, no prospective studies have examined the association between prediagnostic sVEGFR levels and breast cancer risk. We conducted a prospective case-control study nested within the Swedish Mammography Cohort examining the association between sVEGFR2 and 3 levels and breast cancer risk. The analysis included 69 incident breast cancer cases diagnosed after blood collection and 719 controls. Logistic regression models were used to calculate odds ratios and 95% confidence intervals. After adjustment for breast cancer risk factors, sVEGFR2 levels were associated with breast cancer risk (OR=1.28; 95% CI=1.06-1.56 per 1000 ng/L increase in concentration) while sVEGFR3 levels were not related to such risk (OR=1.00; 95% CI=0.93-1.07). Our results suggest that sVEGFR2 levels may be positively associated with breast cancer risk, however future studies with larger case groups are necessary to confirm this association.
Place, publisher, year, edition, pages
2016. Vol. 7, no 1, 81-86 p.
Breast cancer; vascular endothelial growth factor receptor; growth factors; tumor angiogenesis
Cancer and Oncology
IdentifiersURN: urn:nbn:se:uu:diva-294385ISI: 000375132400010PubMedID: 27186332OAI: oai:DiVA.org:uu-294385DiVA: diva2:929716